Lyra Therapeutics, Inc.LYRANASDAQ
Loading
Debt to Equity Over TimeElevated
Percentile Rank100
3Y CAGR+312.2%
5Y CAGR+45.6%
Year-over-Year Change
Debt-to-equity ratio
3Y CAGR
+312.2%/yr
Annual compound
5Y CAGR
+45.6%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
6.5x
Strong expansion
Streak
4 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2024 | 2.97 | +886.4% |
| 2023 | 0.30 | +481.2% |
| 2022 | 0.05 | +22.2% |
| 2021 | 0.04 | +29.3% |
| 2020 | 0.03 | -92.8% |
| 2019 | 0.45 | - |
| 2018 | 0.00 | - |